Dynavax Technologies has submitted a US Biologics License Application (BLA) to the FDA for HEPLISAV, an investigational adult hepatitis B vaccine. In Phase III trials, HEPLISAV demonstrated higher and earlier protection with fewer ...
Biocon has invested in new integrated research and development centre, Biocon Research Center (BRC), in South-East Asia to conduct research on biologics that will deal with unmet medical needs. The 200,000ft2 will accommodate the ...
Tags: Biocon, invested, BRC, research on biologics, South-East Asia
Sanofi and Regeneron Pharmaceuticals have received FDA priority review for the biologics license application (BLA) of ZALTRAP (aflibercept) as a treatment for metastatic colorectal cancer (mCRC). The filing was based on the Phase III ...